Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses | ACS Chemical Neuroscience
Kappa Opioid Receptor Structure Revealed, A Potential Milestone in Medication Development | National Institute on Drug Abuse (NIDA)
IJMS | Free Full-Text | Distinct Effects of Nalmefene on Dopamine Uptake Rates and Kappa Opioid Receptor Activity in the Nucleus Accumbens Following Chronic Intermittent Ethanol Exposure
Enhancing Remyelination through a Novel Opioid-Receptor Pathway | Journal of Neuroscience
Kinase cascades and ligand-directed signaling at the kappa opioid receptor | SpringerLink
Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment - ScienceDirect
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
Z0710N Human Kappa Opioid Receptor (OPRK1) | Montana Molecular
Kappa opioid receptor labeled with Tb (HTRF transiently expressing cells)
Biased Ligands at the Kappa Opioid Receptor: Fine-Tuning Receptor Pharmacology | SpringerLink
Kappa-opioid receptor-dependent changes in dopamine and anxiety-like or approach-avoidance behavior occur differentially across the nucleus accumbens shell rostro-caudal axis - ScienceDirect
Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation | Scientific Reports